Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 21, 2017
Which drugs does patent 8,371,292 protect, and when does it expire?
| Title: | Use of ciclesonide for the treatment of respiratory diseases |
| Abstract: | The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children. |
| Inventor(s): | Bethke; Thomas (Constance, DE), Engelstaetter; Renate (Allensbach, DE), Wurst; Wilhelm (Constance, DE) |
| Assignee: | Nycomed GmbH (Constance, DE) |
| Application Number: | 10/571,311 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; Delivery; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Pharms | OMNARIS | ciclesonide | SPRAY, METERED;NASAL | 022004-001 | Oct 20, 2006 | RX | Yes | Yes | ► Subscribe | ► Subscribe | TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER | ||||||||||||||||||
Astrazeneca Pharms | ZETONNA | ciclesonide | AEROSOL, METERED;NASAL | 202129-001 | Jan 20, 2012 | RX | Yes | Yes | ► Subscribe | ► Subscribe | TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD | ||||||||||||||||||
Astrazeneca Pharms | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-002 | Jan 10, 2008 | RX | Yes | Yes | ► Subscribe | ► Subscribe | MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD | ||||||||||||||||||
Astrazeneca Pharms | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | RX | Yes | Yes | ► Subscribe | ► Subscribe | MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| PCT Information | |||
| PCT Filed | September 15, 2004 | PCT Application Number: | PCT/EP2004/052172 |
| PCT Publication Date: | March 24, 2005 | PCT Publication Number: | WO2005/025578 |
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 2004271744 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2538419 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1117371 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1670482 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1670482 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2452691 | ► Subscribe | |||||||||||||||||||||||||||
| Croatia | P20140257 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2007505829 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2012197306 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5618452 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,719 others who get our Drug Patent Expiration Alerts:
